{{#unlinkedwikibase:id=Q5401860}}
Clinical data | |
---|---|
Trade names | Harmogen, Improvera, Ogen, Ortho-Est, Sulestrex, others |
Other names | Piperazine estrone sulfate; [1] Estrone sulfate piperazine salt; Pipestrone |
AHFS/ Drugs.com | Monograph |
Routes of administration | By mouth |
Drug class | Estrogen |
Identifiers | |
| |
Chemical and physical data | |
Formula | C22H32N2O5S |
Molar mass | 436.57 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Estropipate, sold under the brand name Ogen among others, is a medication used to treat the symptoms of menopause and ovarian failure. [1] It was previously also used to prevent postmenopausal osteoporosis. [1] It is taken by mouth. [1]
Common side effects include headache, breast pain, irregular vaginal bleeding, abdominal cramps, and nausea. [1] Other side effects may include high blood pressure, liver problems, high sugar, swelling, hair loss, and vaginal yeast infections. [1] Rarely blood clots or gallbladder disease may occur. [1] It is an estrogen, specifically a salt of estrone sulfate and piperazine, which is transformed into estrone and estradiol in the body. [2] [3]
Estropipate was first made commercially in the United States in 1950. [4] In the United States 100 tablets of 0.75 mg used to cost about 50 USD. [5] Production; however, has been discontinued in the United States as of 2021. [6] [7]